These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 21585704)

  • 1. An indirect comparison of bevacizumab plus cisplatin-gemcitabine and cisplatin plus pemetrexed treatment for patients with advanced first-line non-squamous non-small cell lung cancer in East Asia.
    Chang JW; Thongprasert S; Wright E; Tsang K; Kim HT; Ahn MJ; Kim JH; Kang JH; Kim SW; Walzer S
    Asia Pac J Clin Oncol; 2011 Jun; 7 Suppl 2():13-21. PubMed ID: 21585704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative effectiveness of bevacizumab plus cisplatin-based chemotherapy versus pemetrexed plus cisplatin treatment in East Asian non-squamous non-small cell lung cancer patients applying real-life outcomes.
    Chang GC; Ahn MJ; Wright E; Kim HT; Kim JH; Kang JH; Kim SW; Sherman S; Walzer S
    Asia Pac J Clin Oncol; 2011 Jun; 7 Suppl 2():34-40. PubMed ID: 21585706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of bevacizumab- and pemetrexed-cisplatin treatment for patients with advanced non-squamous non-small cell lung cancer.
    Nuijten M; Heigener DF; Bischoff HG; Chouaid C; Vergnenègre A; de Castro Carpeño J; Aultman R; Walzer S; Siebert U
    Lung Cancer; 2010 Aug; 69 Suppl 1():S4-10. PubMed ID: 20727460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pemetrexed plus platinum or gemcitabine plus platinum for advanced non-small cell lung cancer: final survival analysis from a multicentre randomized phase II trial in the East Asia region and a meta-analysis.
    Zhang X; Lu J; Xu J; Li H; Wang J; Qin Y; Ma P; Wei L; He J
    Respirology; 2013 Jan; 18(1):131-9. PubMed ID: 22882698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Costs of bevacizumab and pemetrexed for advanced non-squamous NSCLC in Italy and Germany.
    Bischoff HG; Heigener DF; Walzer S; Nuijten M
    Lung Cancer; 2010 Aug; 69 Suppl 1():S18-23. PubMed ID: 20727458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of bevacizumab-based therapy versus cisplatin plus pemetrexed for the first-line treatment of advanced non-squamous NSCLC in Korea and Taiwan.
    Ahn MJ; Tsai CM; Hsia TC; Wright E; Chang JW; Kim HT; Kim JH; Kang JH; Kim SW; Bae EJ; Kang M; Lister J; Walzer S
    Asia Pac J Clin Oncol; 2011 Jun; 7 Suppl 2():22-33. PubMed ID: 21585705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of pemetrexed/cisplatin versus gemcitabine/cisplatin as first-line treatment in Chinese patients with advanced nonsquamous non-small cell lung cancer.
    Wu YL; Lu S; Cheng Y; Zhou C; Wang M; Qin S; Lu Y; Zhang Y; Zhu Y; Song X; Wang X; Barraclough H; Zhang X; Chi H; Orlando M
    Lung Cancer; 2014 Sep; 85(3):401-7. PubMed ID: 25082564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An indirect comparison of the efficacy of bevacizumab plus carboplatin and paclitaxel versus pemetrexed with cisplatin in patients with advanced or recurrent non-squamous adenocarcinoma non-small cell lung cancer.
    Nuijten MJ; Aultman R; Carpeño Jde C; Vergnenègre A; Chouaid C; Walzer S; Siebert U
    Curr Med Res Opin; 2011 Nov; 27(11):2193-201. PubMed ID: 21970659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of cisplatin/pemetrexed versus cisplatin/gemcitabine as first-line treatment in East Asian patients with advanced non-small cell lung cancer: results of an exploratory subgroup analysis of a phase III trial.
    Yang CH; Simms L; Park K; Lee JS; Scagliotti G; Orlando M
    J Thorac Oncol; 2010 May; 5(5):688-95. PubMed ID: 20150825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness analysis of bevacizumab versus pemetrexed for advanced non-squamous NSCLC in Italy.
    Giuliani G; Grossi F; de Marinis F; Walzer S
    Lung Cancer; 2010 Aug; 69 Suppl 1():S11-7. PubMed ID: 20727457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of pemetrexed plus cisplatin with other first-line doublets in advanced non-small cell lung cancer (NSCLC): a combined analysis of three phase 3 trials.
    Treat J; Scagliotti GV; Peng G; Monberg MJ; Obasaju CK; Socinski MA
    Lung Cancer; 2012 May; 76(2):222-7. PubMed ID: 22115704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.
    Scagliotti GV; Parikh P; von Pawel J; Biesma B; Vansteenkiste J; Manegold C; Serwatowski P; Gatzemeier U; Digumarti R; Zukin M; Lee JS; Mellemgaard A; Park K; Patil S; Rolski J; Goksel T; de Marinis F; Simms L; Sugarman KP; Gandara D
    J Clin Oncol; 2008 Jul; 26(21):3543-51. PubMed ID: 18506025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, phase 2 study comparing pemetrexed plus best supportive care versus best supportive care as maintenance therapy after first-line treatment with pemetrexed and cisplatin for advanced, non-squamous, non-small cell lung cancer.
    Mubarak N; Gaafar R; Shehata S; Hashem T; Abigeres D; Azim HA; El-Husseiny G; Al-Husaini H; Liu Z
    BMC Cancer; 2012 Sep; 12():423. PubMed ID: 23006447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of First-Line Necitumumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in East Asian Patients with Stage IV Squamous Non-small Cell Lung Cancer: A Subgroup Analysis of the Phase 3, Open-Label, Randomized SQUIRE Study.
    Park K; Cho EK; Bello M; Ahn MJ; Thongprasert S; Song EK; Soldatenkova V; Depenbrock H; Puri T; Orlando M
    Cancer Res Treat; 2017 Oct; 49(4):937-946. PubMed ID: 28111429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial.
    Barlesi F; Scherpereel A; Gorbunova V; Gervais R; Vikström A; Chouaid C; Chella A; Kim JH; Ahn MJ; Reck M; Pazzola A; Kim HT; Aerts JG; Morando C; Loundou A; Groen HJ; Rittmeyer A
    Ann Oncol; 2014 May; 25(5):1044-52. PubMed ID: 24585722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of bevacizumab with cisplatin and gemcitabine in Asian patients with advanced or recurrent non-squamous non-small cell lung cancer who have not received prior chemotherapy: a substudy of the Avastin in Lung trial.
    Mok TS; Hsia TC; Tsai CM; Tsang K; Chang GC; Chang JW; Sirisinha T; Sriuranpong V; Thongprasert S; Chua DT; Moore N; Manegold C
    Asia Pac J Clin Oncol; 2011 Jun; 7 Suppl 2():4-12. PubMed ID: 21585703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical efficacy of bevacizumab concomitant with pemetrexed in patients with advanced non-small cell lung cancer.
    Zhang YM; Li YQ; Liu ZH; Liao XL; Liang R; Lin Y; Yuan CL; Liao SN; Liang CY; Li Q; Li LQ
    Asian Pac J Cancer Prev; 2014; 15(8):3447-50. PubMed ID: 24870737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies.
    Scagliotti G; Hanna N; Fossella F; Sugarman K; Blatter J; Peterson P; Simms L; Shepherd FA
    Oncologist; 2009 Mar; 14(3):253-63. PubMed ID: 19221167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of pemetrexed as second-line therapy in advanced NSCLC after either treatment-free interval or maintenance therapy with gemcitabine or erlotinib in IFCT-GFPC 05-02 phase III study.
    Bylicki O; Ferlay C; Chouaid C; Lavolé A; Barlési F; Dubos C; Westeel V; Créquit J; Corre R; Vergnenègre A; Monnet I; Le Caer H; Fournel P; Vaylet F; Falchero L; Poudenx M; Linard P; Pérol D; Zalcman G; Pérol M
    J Thorac Oncol; 2013 Jul; 8(7):906-14. PubMed ID: 23591160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A randomized, controlled, multicenter clinical trial comparing pemetrexed/cisplatin and gemcitabine/cisplatin as first-line treatment for advanced nonsquamous non-small cell lung cancer].
    Huang Y; Liu Y; Zhou J; Xu N; Li B; Wu G; Fang J; Li K; Liu X; Liu W; Lu Y; Wang M; Liu W; Liang H; Zhang Y; Huang C; Wang S; Wang Y; Yu S; Chang J; Wang Z; Hu Z; Zhang L
    Zhongguo Fei Ai Za Zhi; 2012 Oct; 15(10):576-82. PubMed ID: 23075681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.